 |
 |
CYTOMEDIX CEO DISCUSSES THE COMPANY AND HIS
LEADERSHIP STYLE IN AN INTERVIEW ON THE LEADERS SPOT WITH
REBECCA BLACKSMITH
ROCKVILLE, MD., April 9,
2009 – Cytomedix, Inc. (NYSE
Alternext US:
GTF) announced today that Chief Executive Officer Martin
Rosendale discussed the company and his leadership style in
an interview on The Leaders Spot with Rebecca Blacksmith.
Mr. Rosendale was a featured guest on The Leaders Spot with
Rebecca Blacksmith, which airs on Washington Business Talk
Radio. His interview aired during the program on April 8,
2009 from 11am-noon on
www.TheLeadersSpot.com and WDMV am 700 and is available
on-demand
24/7 as a podcast at
http://theleadersspot.com/archives/1150. A link to the
podcast is also available on the Company’s website at
www.Cytomedix.com
The Leaders Spot with Rebecca Blacksmith features top
business leaders discussing their respective leadership
styles, philosophies, challenges, successes and industry
trends.
ABOUT THE LEADERS SPOT WITH REBECCA BLACKSMITH
The Leaders Spot with Rebecca Blacksmith is an interview
show hosted by a Leader, about top leaders, for all leaders.
Blacksmith has conducted over 2000 elite interviews and is
currently working on her third Ivy League graduate degree.
Rebecca’s fun and intelligent conversations with these DC
area CEOS and business leaders focus on navigating methods
for serious leadership. For information, visit The Leaders
Spot with Rebecca Blacksmith at
www.TheLeadersSpot.com.
ABOUT CYTOMEDIX
Cytomedix is a biotechnology company that develops,
sells, and licenses regenerative biological therapies,
including the AutoloGel™ System, a device for the production
of platelet rich plasma ("PRP'') gel derived from the
patient's own blood. The AutoloGel™ System is cleared by the
Food and Drug Administration ("FDA'') for use on a variety
of exuding wounds. Additional information regarding
Cytomedix is available at:
http://www.cytomedix.com
SAFE HARBOR STATEMENT
Statements contained in this communication, and the referenced interview, not relating to
historical facts are forward-looking statements that are intended to fall within the safe harbor
rule for such statements under the Private Securities Litigation Reform Act of 1995. The
information contained in the forward-looking statements is inherently uncertain, and Cytomedix's
actual results may differ materially due to a number of factors, many of which are beyond
Cytomedix's ability to predict or control, including among others, commercial success or
acceptance by the medical community, competitive responses, the Company’s ability to raise
additional capital and to continue as a going concern, viability and effectiveness of the
Company's sales approach and overall marketing strategies, and Cytomedix's ability to execute
on its strategy to market the AutoloGelTM System as contemplated. These forward-looking
statements are subject to known and unknown risks and uncertainties that could cause actual
events to differ from the forward-looking statements. More information about some of these risks
and uncertainties may be found in the reports filed with the Securities and Exchange
Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly
changing business and regulatory environment, thus new or unforeseen risks may arise.
Accordingly, investors should not place any reliance on forward-looking statements as a
prediction of actual results. Except as is expressly required by the federal securities laws,
Cytomedix undertakes no obligation to update or revise any forward-looking statements,
whether as a result of new information, changed circumstances or future events or for any other
reason.
|
|